Brief: Timber Says First Patients Enrolled In Phase 3 Ascend Clinical Trial Evaluating TMB-001 In Congenital Ichthyosis
23/06/2022 13:24
June 23 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS ANNOUNCES FIRST PATIENTS ENROLLED
IN
PHASE 3 ASCEND CLINICAL TRIAL EVALUATING TMB-001 IN CONGENITAL
ICHTHYOSIS
Source text for Eikon: ID:nGNX3VmXm0
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing